 CAMBRIDGE, Mass.--BUSINESS WIRE--Epizyme, Nasdaq: EPZM, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the company has entered into an amended and restated agreement with funds managed by Pharmakon Advisors, LP, an affiliate of Royalty Pharma, to expand its loan facility and plans to draw down 150 million. Epizyme and Pharmakon Advisors originally executed their agreement in November 2019, in conjunc 